{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:40:19Z","timestamp":1651138819135},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00108-021-01250-3","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T19:03:36Z","timestamp":1642705416000},"page":"566-572","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Innovationen in der Arzneimitteltherapie des systemischen Lupus erythematodes"],"prefix":"10.1007","volume":"63","author":[{"given":"Johanna","family":"Mucke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"1250_CR1","unstructured":"Aranow\u00a0C, Allaart\u00a0C, Amoura\u00a0Z et\u00a0al (2021) Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: the phase\u00a03, randomized, placebo-controlled BLISS-BELIEVE study. Arthritis Rheumatol 73(Suppl\u00a010). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-subcutaneous-belimumab-bel-and-rituximab-rtx-sequential-therapy-in-patients-with-systemic-lupus-erythematosus-the-phase-3-randomized-placebo-controlled-bliss-believe-stud\/"},{"issue":"1","key":"1250_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.41466","volume":"73","author":"Y Atisha-Fregoso","year":"2021","unstructured":"Atisha-Fregoso\u00a0Y, Malkiel\u00a0S, Harris\u00a0KM et al (2021) Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis Rheumatol 73(1):121\u2013131","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"1250_CR3","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1136\/annrheumdis-2017-211388","volume":"76","author":"C Chamberlain","year":"2017","unstructured":"Chamberlain\u00a0C, Colman\u00a0PJ, Ranger\u00a0AM et\u00a0al (2017) Repeated administration of dapirolizumab pegol in a\u00a0randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Ann Rheum Dis 76(11):1837\u20131844","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1250_CR4","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/art.41598","volume":"73","author":"WW Chatham","year":"2021","unstructured":"Chatham\u00a0WW, Furie\u00a0R, Saxena\u00a0A et al (2021) Long-term safety and efficacy of anifrolumab in adults with systemic lupus erythematosus: results of a\u00a0phase II open-label extension study. Arthritis Rheumatol 73(5):816\u2013825","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1250_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Alunno\u00a0A et\u00a0al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1250_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Cheema\u00a0K et al (2020) 2019 update of the joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1250_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00393-020-00785-4","volume":"80","author":"C Fiehn","year":"2021","unstructured":"Fiehn\u00a0C, Ness\u00a0T, Weseloh\u00a0C et al (2021) Sicherheitsmanagement der Therapie mit Antimalariamitteln in der Rheumatologie. Interdisziplin\u00e4re Empfehlungen auf der Basis einer systematischen Literatur-Recherche. Z\u00a0Rheumatol 80(1):1\u20139","journal-title":"Z Rheumatol"},{"key":"1250_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"3","author":"R Furie","year":"2019","unstructured":"Furie\u00a0R, Werth\u00a0VP, Merola\u00a0JF et\u00a0al (2019) Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J\u00a0Clin Invest 3:1359\u20131371","journal-title":"J Clin Invest"},{"key":"1250_CR9","unstructured":"Furie\u00a0R, van Vollenhoven\u00a0R, Kalunian\u00a0K et\u00a0al (2020) Efficacy and safety results from a\u00a0phase\u00a02, randomized, double-blind trial of BIIB059, an anti-blood dendritic cell antigen\u00a02 antibody, in SLE. Arthritis Rheumatol 72(Suppl\u00a010). https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-results-from-a-phase-2-randomized-double-blind-trial-of-biib059-an-anti-blood-dendritic-cell-antigen-2-antibody-in-sle\/"},{"issue":"12","key":"1250_CR10","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie\u00a0R, Rovin\u00a0BH, Houssiau\u00a0F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N\u00a0Engl J Med 383(12):1117\u20131128","journal-title":"N Engl J Med"},{"issue":"8","key":"1250_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/09612033211014267","volume":"30","author":"R Furie","year":"2021","unstructured":"Furie\u00a0R, Morand\u00a0EF, Askanase\u00a0AD et\u00a0al (2021) Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus 30(8):1254\u20131263","journal-title":"Lupus"},{"key":"1250_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","author":"RA Furie","year":"2021","unstructured":"Furie\u00a0RA, Aroca\u00a0G, Cascino\u00a0MD et al (2021) B\u2011cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1250_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","volume":"79","author":"J He","year":"2020","unstructured":"He\u00a0J, Zhang\u00a0R, Shao\u00a0M et al (2020) Efficacy and safety of low-dose IL\u20112 in the treatment of systemic lupus erythematosus: a\u00a0randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 79(1):141\u2013149","journal-title":"Ann Rheum Dis"},{"key":"1250_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3389\/fimmu.2020.00433","volume":"11","author":"C Kaegi","year":"2020","unstructured":"Kaegi\u00a0C, Steiner\u00a0UC, Wuest\u00a0B et al (2020) Systematic review of safety and efficacy of atacicept in treating immune-mediated disorders. Front Immunol 11:433","journal-title":"Front Immunol"},{"issue":"1","key":"1250_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill\u00a0JT, Neuwelt\u00a0CM, Wallace\u00a0DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1250_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/annrheumdis-2021-eular.1471","volume":"80","author":"JT Merrill","year":"2021","unstructured":"Merrill\u00a0JT, Werth\u00a0V, Furie\u00a0R et\u00a0al (2021) OP0131 anifrolumab effects on rash and arthritis in patients with Sle and impact of interferon signal in pooled data from phase 3 trials. Ann Rheum Dis 80(1):75\u201376","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1250_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382(3):211\u2013221","journal-title":"N Engl J Med"},{"issue":"6","key":"1250_CR18","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D, Kr\u00f6nke\u00a0G, V\u00f6lkl\u00a0S et al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N\u00a0Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"3","key":"1250_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.120.048238","volume":"142","author":"LS Nguyen","year":"2020","unstructured":"Nguyen\u00a0LS, Dolladille\u00a0C, Drici\u00a0M\u2011D et al (2020) Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the world health organization pharmacovigilance database. Circulation 142(3):303\u2013305","journal-title":"Circulation"},{"issue":"9","key":"1250_CR20","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2016-210882","volume":"76","author":"J Ordi-Ros","year":"2017","unstructured":"Ordi-Ros\u00a0J, S\u00e1ez-Comet\u00a0L, P\u00e9rez-Conesa\u00a0M et al (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a\u00a0randomised clinical trial. Ann Rheum Dis 76(9):1575\u20131582","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1250_CR21","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/lupus-2018-000261","volume":"5","author":"JM Riggs","year":"2018","unstructured":"Riggs\u00a0JM, Hanna\u00a0RN, Rajan\u00a0B et al (2018) Characterisation of anifrolumab, a\u00a0fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus. Lupus Sci Med 5(1):e261","journal-title":"Lupus Sci Med"},{"issue":"4","key":"1250_CR22","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","volume":"64","author":"BH Rovin","year":"2012","unstructured":"Rovin\u00a0BH, Furie\u00a0R, Latinis\u00a0K et\u00a0al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64(4):1215\u20131226","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1250_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","volume":"95","author":"BH Rovin","year":"2019","unstructured":"Rovin\u00a0BH, Solomons\u00a0N, Pendergraft\u00a0WF et al (2019) A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int 95(1):219\u2013231","journal-title":"Kidney Int"},{"issue":"10289","key":"1250_CR24","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Teng\u00a0YKO, Ginzler\u00a0EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a\u00a0double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397(10289):2070\u20132080","journal-title":"Lancet"},{"issue":"1","key":"1250_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/ard.2008.101766","volume":"69","author":"G Ruiz-Irastorza","year":"2010","unstructured":"Ruiz-Irastorza\u00a0G, Ramos-Casals\u00a0M, Brito-Zeron\u00a0P et al (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a\u00a0systematic review. Ann Rheum Dis 69(1):20\u201328","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1250_CR26","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1177\/0961203320930099","volume":"29","author":"G Ruiz-Irastorza","year":"2020","unstructured":"Ruiz-Irastorza\u00a0G, Ugarte\u00a0A, Ruiz-Arruza\u00a0I et al (2020) Seventy years after Hench\u2019s Nobel prize: revisiting the use of glucocorticoids in systemic lupus erythematosus. Lupus 29(10):1155\u20131167","journal-title":"Lupus"},{"issue":"1","key":"1250_CR27","doi-asserted-by":"publisher","first-page":"e000252","DOI":"10.1136\/lupus-2017-000252","volume":"5","author":"R Tummala","year":"2018","unstructured":"Tummala\u00a0R, Rouse\u00a0T, Berglind\u00a0A et\u00a0al (2018) Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers. Lupus Sci Med 5(1):e252","journal-title":"Lupus Sci Med"},{"issue":"5","key":"1250_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/art.41179","volume":"72","author":"RF van Vollenhoven","year":"2020","unstructured":"van Vollenhoven\u00a0RF, Hahn\u00a0BH, Tsokos\u00a0GC et al (2020) Maintenance of efficacy and safety of ustekinumab through one year in a\u00a0phase II multicenter, prospective, randomized, double-blind, placebo-controlled crossover trial of patients with active systemic lupus erythematosus. Arthritis Rheumatol 72(5):761\u2013768","journal-title":"Arthritis Rheumatol"},{"issue":"10143","key":"1250_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace\u00a0DJ, Furie\u00a0RA, Tanaka\u00a0Y et al (2018) Baricitinib for systemic lupus erythematosus: a\u00a0double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392(10143):222\u2013231","journal-title":"Lancet"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01250-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01250-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:03:48Z","timestamp":1651136628000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01250-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01250-3","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J. Mucke erhielt Beratungs- und Referentenhonorare von AbbVie, Amgen, AstraZeneca, BMS, Celgene, Gilead Sciences, Galapagos, GlaxoSmithKline, Janssen-Cilag, Lilly, Medac, Mylan und Novartis Pharma, sowie wissenschaftliche F\u00f6rderung von Sanofi.M. Schneider erhielt Beratungs- und Referentenhonorare von MSD, Abbott, AbbVie, Pfizer, GlaxoSmithKline, UCB, Roche, AstraZeneca, Lilly, Janssen-Cilag, Sanofi-Aventis, Chugai, Celgene, Novartis, Boehringer Ingelheim und Bristol-Myers Squibb.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}